Akums receives EU GMP approval for two manufacturing units in Haridwar

Delhi: Akums Drugs & Pharmaceuticals Ltd recently acquired the stringent European Union (EU) Good Manufacturing Practice (GMP) approval for two of their manufacturing units in Haridwar. Following this prestigious nod, the gateway for several new opportunities in the European and other stringent regulatory markets is open to Akums Drugs.

The company received EU GMP approval for two of their manufacturing plants. One plant manufactures solid oral dosage forms such as tablets, hard gelatin capsules, powders in sachets, etc belonging to the general category, and the other manufactures the large-volume and small-volume parenterals range including vials, ampoules, eyedrops, FFS as well as dry powder injections belonging to the penicillin line.

Sandeep Jain, Founder, Akums Drugs & Pharmaceuticals, said, “We are happy to announce that Akums Drugs has received the EU GMP approval for two of our Haridwar-based manufacturing facilities, thus paving the path for new opportunities from the entire EU as well as many other regulatory markets. We are already the largest Indian contract manufacturing company, manufacturing over 12 per cent of the country’s domestic supply. Congratulations to the entire team, and hope this is the beginning of numerous possibilities for us.”

Sanjeev Jain, Director, Akums Drugs & Pharmaceuticals said, “Akums is already exporting to over 50 countries around the world. With the esteemed EU GMP nod, now we have gained access to the most stringent of global pharmaceutical markets beside the US. These include the entire European Union, and other markets like South Africa, Canada, Malaysia, Indonesia, Thailand, Australia/New Zealand and most middle-eastern countries.”